U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29NO2.C10H8O3S.H2O
Molecular Weight 565.7225
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROPOXYPHENE NAPSYLATE

SMILES

CCC(=O)O[C@@](Cc1ccccc1)([C@]([H])(C)CN(C)C)c2ccccc2.c1ccc2cc(ccc2c1)S(=O)(=O)O.O

InChI

InChIKey=GBKONKCASNNUQD-VGHSCWAPSA-N
InChI=1S/C22H29NO2.C10H8O3S.H2O/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19;11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10;/h6-15,18H,5,16-17H2,1-4H3;1-7H,(H,11,12,13);1H2/t18-,22+;;/m1../s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6151117 | https://www.ncbi.nlm.nih.gov/pubmed/21215785 | https://www.drugs.com/propoxyphene.html

LEVOPROPOXYPHENE is an antitussive drug, one of enantiomer of propoxyphene. Pdropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company. Pdropoxyphene is intended to treat mild pain and also has antitussive (cough suppressant) and local anaesthetic effects.

Originator

Sources: Archives internationales de pharmacodynamie et de therapie (1955), 104, (2), 156-66.http://pubs.acs.org/doi/abs/10.1021/jo01044a530

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
53.0 nM [Kd]
140.0 nM [Kd]
2100.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DARVON COMPOUND-65

Approved Use

This product is indicated for the relief of mild to moderate pain, either when pain is present alone or when it is accompanied by fever.

Launch Date

-3.83011193E11
Primary
NOVRAD

Approved Use

Unknown

Launch Date

-2.45635203E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2310 ng/mL
7.5 mg/kg single, oral
dose: 7.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORPROPOXYPHENE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
459 ng/mL
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NORPROPOXYPHENE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
126000 ng × h/mL
7.5 mg/kg single, oral
dose: 7.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORPROPOXYPHENE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2440 ng × h/mL
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NORPROPOXYPHENE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4 h
7.5 mg/kg single, oral
dose: 7.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORPROPOXYPHENE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
NORPROPOXYPHENE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1700 mg, 1 times / day
Sources:
unhealthy, 29 years
n = 1
Health Status: unhealthy
Condition: heroin dependence
Age Group: 29 years
Sex: M
Population Size: 1
Sources:
Other AEs: Seizure...
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Disc. AE: Emesis, Blurred vision...
Other AEs: Feeling detached, Dizziness...
AEs leading to
discontinuation/dose reduction:
Emesis (3.1%)
Blurred vision (3.1%)
Other AEs:
Feeling detached (12.5%)
Dizziness (3.1%)
Drowsiness (6.2%)
Nervous (6.2%)
Shaking (6.2%)
Headaches (6.2%)
Hangover (3.1%)
Taste metallic (6.2%)
Cramps leg (3.1%)
Upset stomach (6.2%)
Constipation (6.2%)
Sources:
200 mg 1 times / day single, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: single
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Other AEs: Dizziness, Diaphoresis...
Other AEs:
Dizziness (grade 3, 4.2%)
Diaphoresis (grade 3, 2.1%)
Sources:
800 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, adult
n = 272
Health Status: unhealthy
Condition: heroin dependence
Age Group: adult
Sex: M+F
Population Size: 272
Sources:
Other AEs: Dysphoria...
800 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, mean age 28.5 years
n = 32
Health Status: unhealthy
Condition: heroin dependence
Age Group: mean age 28.5 years
Sex: M+F
Population Size: 32
Sources:
Other AEs: Constipation, Delirium...
Other AEs:
Constipation
Delirium
Dysphoria
Euphoria
Sedation
Sources:
100 mg 6 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 6 times / day
Route: oral
Route: multiple
Dose: 100 mg, 6 times / day
Sources:
unhealthy, adult
n = 50
Health Status: unhealthy
Condition: nonproductive cough
Age Group: adult
Sex: M+F
Population Size: 50
Sources:
Disc. AE: Nausea...
AEs leading to
discontinuation/dose reduction:
Nausea
Sources:
AEs

AEs

AESignificanceDosePopulation
Seizure
1700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1700 mg, 1 times / day
Sources:
unhealthy, 29 years
n = 1
Health Status: unhealthy
Condition: heroin dependence
Age Group: 29 years
Sex: M
Population Size: 1
Sources:
Feeling detached 12.5%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Cramps leg 3.1%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Dizziness 3.1%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Hangover 3.1%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Blurred vision 3.1%
Disc. AE
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Emesis 3.1%
Disc. AE
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Constipation 6.2%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Drowsiness 6.2%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Headaches 6.2%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Nervous 6.2%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Shaking 6.2%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Taste metallic 6.2%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Upset stomach 6.2%
1000 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Sources:
unhealthy, adult
n = 32
Health Status: unhealthy
Condition: heroin and methadone dependence
Age Group: adult
Sex: M+F
Population Size: 32
Sources:
Diaphoresis grade 3, 2.1%
200 mg 1 times / day single, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: single
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Dizziness grade 3, 4.2%
200 mg 1 times / day single, oral
Studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: single
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Condition: pain
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Dysphoria grade 1
800 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, adult
n = 272
Health Status: unhealthy
Condition: heroin dependence
Age Group: adult
Sex: M+F
Population Size: 272
Sources:
Constipation
800 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, mean age 28.5 years
n = 32
Health Status: unhealthy
Condition: heroin dependence
Age Group: mean age 28.5 years
Sex: M+F
Population Size: 32
Sources:
Delirium
800 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, mean age 28.5 years
n = 32
Health Status: unhealthy
Condition: heroin dependence
Age Group: mean age 28.5 years
Sex: M+F
Population Size: 32
Sources:
Dysphoria
800 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, mean age 28.5 years
n = 32
Health Status: unhealthy
Condition: heroin dependence
Age Group: mean age 28.5 years
Sex: M+F
Population Size: 32
Sources:
Euphoria
800 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, mean age 28.5 years
n = 32
Health Status: unhealthy
Condition: heroin dependence
Age Group: mean age 28.5 years
Sex: M+F
Population Size: 32
Sources:
Sedation
800 mg 1 times / day multiple, oral (starting)
Studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, mean age 28.5 years
n = 32
Health Status: unhealthy
Condition: heroin dependence
Age Group: mean age 28.5 years
Sex: M+F
Population Size: 32
Sources:
Nausea Disc. AE
100 mg 6 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 6 times / day
Route: oral
Route: multiple
Dose: 100 mg, 6 times / day
Sources:
unhealthy, adult
n = 50
Health Status: unhealthy
Condition: nonproductive cough
Age Group: adult
Sex: M+F
Population Size: 50
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
major [Ki 3.5 uM]
no [Activation >10 uM]
no [Activation >10 uM]
no [Activation >10 uM]
yes [Activation 5.01187 uM]
yes [Activation 7.94328 uM]
yes [IC50 63.3 uM]
yes
yes
yes (co-administration study)
Comment: Propoxyphene inhibits CYP2D6-mediated hepatic clearance of metoprolol
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Transdermal clonidine: does it affect pain after abdominal hysterectomy?
2003
Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002).
2003 Aug
Co-proxamol and suicide: Licence needs to be changed.
2003 Aug 2
Dependence on legal psychotropic drugs among alcoholics.
2003 Nov-Dec
[Impact of 2 strategies of analgesia on postoperative pain after emergency hand surgery performed on an ambulatory basis].
2003 Oct
Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry.
2003 Oct 10
The effect of preincisional periportal infiltration with ropivacaine in pain relief after laparoscopic procedures: a prospective, randomized controlled trial.
2003 Oct-Dec
30-MINUTES-TUMT. Use of the visual analogue scale to investigate patients' pain perception, different cocktail options and tolerability during 30 minutes' treatment.
2004
Titanium pigment in tissues of drug addicts: report of 5 necropsied cases.
2004 Apr
Weak opiate analgesics: modest practical merits.
2004 Feb
Characterizing the subjective, psychomotor, and physiological effects of oral propoxyphene in non-drug-abusing volunteers.
2004 Feb 7
Self-reported drug use and urinalysis results.
2004 Jan
Propoxyphene use in the elderly.
2004 Jul
A population-based study of pain and quality of life during the year before death in men with prostate cancer.
2004 Mar 22
[Plasma assay of methadone enantiomers with high performance liquid chromatography].
2004 May
Improvement of pain treatment after major abdominal surgery by intravenous S+-ketamine.
2004 May
CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement.
2004 Oct
Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom.
2004 Oct 15
Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches.
2004 Sep
Criteria for prescribing require further study.
2004 Sep
The occurrence of selected human pharmaceutical compounds in UK estuaries.
2004 Sep
Intermittent injection of bupivacaine into the margin or the cavity after reduction mammaplasty.
2005
Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids.
2005
ECG abnormalities in co-proxamol (paracetamol/dextropropoxyphene) poisoning.
2005
Dextropropoxyphene: safety and efficacy in older patients.
2005
Simultaneous determination of paracetamol and dextropropoxyphene in human plasma by liquid chromatography/tandem mass spectrometry: application to clinical bioequivalence studies.
2005
Relation of postmortem blood alcohol and drug concentrations in fatal poisonings involving amitriptyline, propoxyphene and promazine.
2005 Aug
Paracetamol + dextropropoxyphene: planned withdrawal from the British market.
2005 Aug
Usage of paracetamol-containing combination analgesics remains high in primary care.
2005 Dec
A multicentre study of coproxamol poisoning suicides based on coroners' records in England.
2005 Feb
Opioid poisoning deaths in New Zealand (2001-2002).
2005 Feb 11
The role of tramadol in cancer pain treatment--a review.
2005 Jan
Acute pain management pharmacology for the patient with concurrent renal or hepatic disease.
2005 Jun
A randomized, double-blind, placebo controlled triphosphate in study of oral adenosine subacute low back pain.
2005 Jun
Impact of paracetamol pack size restrictions on poisoning from paracetamol in England and Wales: an observational study.
2005 Mar
Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study.
2005 May
Clinical toxicology: clinical science to public health.
2005 Nov
Bupivacaine/ketamine is superior to intra-articular ketamine analgesia following arthroscopic knee surgery.
2005 Oct
Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network.
2005 Sep
Drug therapy in dental practice: nonopioid and opioid analgesics.
2005 Winter
Time-trends in method-specific suicide rates compared with the availability of specific compounds. The Danish experience.
2006
Dextropropoxyphene combinations: Swedish market withdrawal.
2006 Feb
Analgesic effect of electroacupuncture in postthoracotomy pain: a prospective randomized trial.
2006 Jun
Consumer group urges Food and Drug Administration to ban drug Darvon.
2006 Jun
Development of opioid formulations with limited diversion and abuse potential.
2006 Jun
[Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
2006 Mar
Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene.
2006 Mar
Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.
2006 Mar
Propoxyphene-induced hypoglycemia in renal failure.
2006 Mar-Apr
Survival after marked hyperlactaemia.
2006 May
Patents

Sample Use Guides

Darvon-N (Propoxyphene) is given orally. The usual dosage is one 100 mg propoxyphene napsylate tablet every 4 hours as needed for pain. The maximum dose of Darvon-N is 6 tablets per day. Do not exceed the maximum daily dose.
Route of Administration: Oral
Cell membrane preparation (Chemiscreen™ MOR) expressing recombinant human MOR were used for activity evaluation. The assays were performed in microtiter plates with 40 mkL of binding buffer or Propoxyphene (1–100,000 mkM), 10 mkL of radioligand (2 nM (3H)-DAMG), and 50 mkL of diluted membranes with three wells per group. The plates were then incubated at room temperature for 2h. The binding incubation was terminated by the addition of 100 mkL cold binding buffer to each well. The glass fiber filter plates were presoaked for 30–45 min with 0.33% PEI buffer. The PEI solution was removed from the filter plate with a vacuum manifold (Millipore) and the filters washed with 200 mkL priming buffer (50 mM HEPES, 0.5% BSA, pH 7.4) per well. The binding reaction was transferred to the filter plate and washed with 200 mkL washing buffer (50 mM HEPES with 500 mM NaCl and 0.1% BSA, pH 7.4).
Name Type Language
PROPOXYPHENE NAPSYLATE
ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
PROPOXYPHENE NAPSYLATE [ORANGE BOOK]
Common Name English
(.ALPHA.S,1R)-.ALPHA.-(2-(DIMETHYLAMINO)-1-METHYLETHYL)-.ALPHA.-PHENYLPHENETHYL PROPIONATE COMPOUND WITH 2-NAPHTHALENESULFONIC ACID (1:1) MONOHYDRATE
Common Name English
BENZENEETHANOL, .ALPHA.-(2-(DIMETHYLAMINO)-1-METHYLETHYL)-.ALPHA.-PHENYL-, PROPANOATE (ESTER), (S-(R*,S*))-, COMPD. WITH 2-NAPHTHALENESULFONIC ACID (1:1), MONOHYDRATE
Common Name English
DEXTROPROPOXYPHENE NAPSILATE MONOHYDRATE
Common Name English
PROPOXYPHENE NAPSYLATE MONOHYDRATE [MI]
Common Name English
DEXTROPROPOXYPHENE NAPSILATE [MART.]
Common Name English
D-PROPOXYPHENE NAPSYLATE HYDRATE
Common Name English
DARVON-N
Brand Name English
DEXTROPROPOXYPHENE NAPSILATE [WHO-DD]
Common Name English
PROPOXYPHENE NAPSYLATE [VANDF]
Common Name English
PROPOXYPHENE NAPSYLATE [USAN]
Common Name English
PROPOXYPHENE NAPSYLATE [USP]
Common Name English
DEXTROPROPOXYPHENE NAPSILATE
MART.   WHO-DD  
Common Name English
PROPOXYPHENE NAPSYLATE CII
USP-RS  
Common Name English
DEXTROPROPOXYPHENE NAPSYLATE MONOHYDRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1506
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
NCI_THESAURUS C67413
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
DEA NO. 9752
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
Code System Code Type Description
PUBCHEM
33544
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
EVMPD
SUB127378
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
MERCK INDEX
M9222
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY Merck Index
DRUG BANK
DBSALT001000
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
MESH
C084813
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
WIKIPEDIA
Propoxyphene napsylate
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
NCI_THESAURUS
C29386
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
RXCUI
8786
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL1213351
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
EVMPD
SUB127448
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
FDA UNII
38M219L1OJ
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
EVMPD
SUB01650MIG
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
EVMPD
SUB126063
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY
CAS
26570-10-5
Created by admin on Sat Jun 26 12:58:38 UTC 2021 , Edited by admin on Sat Jun 26 12:58:38 UTC 2021
PRIMARY